The relentless advance of antibiotic drug resistant bacteria has raised concerns whether within the next 2-3 decades we could be facing a ‘pre-antibiotic era’ where existing antibiotics will become largely ineffective in treating serious and life-threatening infections. Indeed, the World Health Organization has projected that the impact on human health and economic costs associated with antibiotic drug resistance will rival that of global warming (amr-review.org). Whereas continued improvements to existing antibiotics certainly stretch such timelines, entirely new classes of antibiotics with novel mechanisms of action are urgently needed to combat multi-drug resistant bacteria.
At Prokaryotics Inc., we have assembled a world class team of industry experts, academic leaders, and innovative proprietary assets to develop next generation antibiotics to combat this crisis. Each of our Prokaryotics antibiotic development programs uniquely target distinct cell surface and fundamentally essential biochemical assembly components of the Gram-negative outer membrane; an intrinsic barrier produced by Gram-negative bacteria which naturally restricts antibiotic entry and ultimate efficacy. We believe targeting a circuitry of interdependent cellular processes required for outer membrane biogenesis provides a timely and robust opportunity to develop next generation antibiotic agents effective on their own or in combination with existing agents to provide effective monotherapeutic or synergistic efficacy against drug-resistant bacteria.
Prokaryotics' offices and laboratories are located within the Institute for Life Science Entrepreneurship (ILSE) in Union, New Jersey. ILSE is a non-profit 501(c)(3) research institute supporting the creation of life-science companies in the New Jersey region and helping existing businesses expand and succeed. ILSE provides incubator space for 6-8 start-up companies, a central services lab offering in-house research services, an external network of laboratories providing a full suite of discovery to IND services, and a network of consultants with a full range of drug R&D expertise. Through ILSE, Prokaryotics benefits from a rich intellectual environment where scientific innovation thrives and collaboration in the biopharmaceutical industry is fostered.